Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: pioglitazone


Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors

June 21st 2020

Pioglitazone use decreased the risk of new-onset ischemic stroke in Asian patients with type 2 DM and CV risk factors (Cardiovascular Diabetology)

Categories: Medication, News
Tags: pioglitazone, Type 2 Diabetes

Categories: Medication
Tags: pioglitazone, Type 2 Diabetes

Diabetes medications with cardiovascular protection as we enter a new decade

June 10th 2020

Can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and metformin complement each other to save lives? (ABCD)

Categories: Medication, News
Tags: GLP1, metformin, pioglitazone, SGLT2 inhibitors

Categories: Medication
Tags: GLP1, metformin, pioglitazone, SGLT2 inhibitors

IDF Diabetes Atlas: A review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018

November 14th 2019

This study illustrated difficulties in deriving a meaningful global prevalence rate for DR and DME due to the lack of uniformity in defining the study populations, methodological differences, retinal image capture and grading criteria. Therefore, international consensus is required using a minimal data set for future studies (Diabetes Research and Clinical Practice)

Categories: Audits, News
Tags: DME, pioglitazone, retinopathy

Categories: Audits
Tags: DME, pioglitazone, retinopathy

Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study

January 20th 2018

This analysis suggests that pioglitazone is associated with a decrease in both cardiovascular and non-cardiovascular mortality. Results should be interpreted with caution due to the potential for residual confounding in this exploratory analysis. Further studies, specifically designed to test the association between pioglitazone use and patient-focused outcomes, are suggested (BMJ)

Categories: Medication, News
Tags: mortality, pioglitazone

Categories: Medication
Tags: mortality, pioglitazone

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial

September 13th 2017

In this long-term, pragmatic trial, incidence of cardiovascular events was similar with sulfonylureas (mostly glimepiride and gliclazide) and pioglitazone as add-on treatments to metformin. Both of these widely available and affordable treatments are suitable options with respect to efficacy and adverse events, although pioglitazone was associated with fewer hypoglycaemia events (The Lancet Diabetes & Endocrinology)

Categories: Cardiovascular, News
Tags: metformin, pioglitazone, sulfonylureas, Type 2 Diabetes

Categories: Cardiovascular
Tags: metformin, pioglitazone, sulfonylureas, Type 2 Diabetes

Effects of Pioglitazone on the Incidence of Dementia in Patients with Diabetes

February 8th 2017

Pioglitazone is a time- and dose-dependent protective factor against dementia in patients with diabetes. The risk of dementia is lower in long-term and high-dose pioglitazone users than in never users of pioglitazone (Journal of Diabetes and Its Complications)

Categories: Medication, News
Tags: dementia, pioglitazone

Categories: Medication
Tags: dementia, pioglitazone

Evaluation of exposure to pioglitazone and risk of prostate cancer: a nested case–control study

December 13th 2016

In this real-world, nested matched case–control study, exposure to pioglitazone was not associated with increased risk of prostate cancer (BMJ Open, Diabetes Research & Care)

Categories: Medication, News
Tags: pioglitazone, prostate cancer

Categories: Medication
Tags: pioglitazone, prostate cancer

Pioglitazone (Actos) and Bladder Cancer: Legal System Triumphs Over the Evidence

April 12th 2016

To limit their legal costs, the pharmaceutical company has established a 2.4 billion dollar settlement pool. So much for evidence-based medicine (Journal of Diabetes and Its Complications)

Categories: Medication, News
Tags: bladder cancer, legal, pioglitazone

Categories: Medication
Tags: bladder cancer, legal, pioglitazone

Pioglitazone use and risk of bladder cancer: population based cohort study

March 31st 2016

The results of this large population based study indicate that pioglitazone is associated with an increased risk of bladder cancer. The absence of an association with rosiglitazone suggests that the increased risk is drug specific and not a class effect (BMJ)

Categories: Medication, News
Tags: bladder cancer, pioglitazone

Categories: Medication
Tags: bladder cancer, pioglitazone

Revitalization of Pioglitazone: The Optimal Agent to be Combined with an SGLT2 Inhibitor

February 25th 2016

Herein, we provide an overview of the potential benefits of combined pioglitazone/empagliflozin therapy to prevent cardiovascular events in patients with type 2 diabetes mellitus (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: pioglitazone, Type 2 Diabetes

Categories: Medication
Tags: pioglitazone, Type 2 Diabetes

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

February 18th 2016

In this trial involving patients without diabetes who had insulin resistance along with a recent history of ischemic stroke or TIA, the risk of stroke or myocardial infarction was lower among patients who received pioglitazone than among those who received placebo (NEJM)

Categories: Cardiovascular, News
Tags: pioglitazone, stroke, TIA

Categories: Cardiovascular
Tags: pioglitazone, stroke, TIA

Combined Intervention With Pioglitazone and n-3 Fatty Acids in Metformin-treated Type 2 Diabetic Patients

February 16th 2016

Besides preventing a modest negative effect of n-3 fatty acids on glycemic control, the combination of pioglitazone and EPA + DHA can be used to improve lipid metabolism in T2D patients on stable metformin therapy (Medscape) – Registration required

Categories: Medication, News
Tags: n-3 fatty acids, pioglitazone

Categories: Medication
Tags: n-3 fatty acids, pioglitazone

Diabetes medications with cardiovascular protection in the wake of EMPA-REG OUTCOME

December 1st 2015

The optimal combination may be metformin, pioglitazone and empagliflozin  (British Journal of Diabetes & Vascular Disease)

Categories: Medication, News
Tags: Empagliflozin, metformin, pioglitazone

Categories: Medication
Tags: Empagliflozin, metformin, pioglitazone

Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes

July 21st 2015

Pioglitazone use was not associated with a statistically significant increased risk of bladder cancer, although an increased risk, as previously observed, could not be excluded (JAMA)

Categories: Medication, News
Tags: bladder cancer, pioglitazone

Categories: Medication
Tags: bladder cancer, pioglitazone

Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease

July 21st 2015

This observational study indicated a protective association of pioglitazone with cardiovascular disease and death in type 2 diabetic subjects without established vascular disease, particularly those with nephropathy (Diabetes Research and Clinical Practice)

Categories: Cardiovascular, News
Tags: pioglitazone

Categories: Cardiovascular
Tags: pioglitazone

Continuation or discontinuation of pioglitazone when starting bedtime insulin in patients with poorly controlled type 2 diabetes in an inner-city population

July 2nd 2015

We conclude that in patients with uncontrolled type 2 DM, continuing pioglitazone while concurrently starting bedtime insulin within a 13-month period led to a significant decrease in both HbA1c and FPG levels compared with those who did not receive pioglitazone; however weight increased during this period (Journal of Diabetes and Its Complications)

Categories: Medication, News
Tags: pioglitazone

Categories: Medication
Tags: pioglitazone

Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis

April 8th 2015

The cumulative use of pioglitazone or rosiglitazone was not associated with the incidence of bladder cancer in this large, pooled multipopulation analysis (Diabetologia)

Categories: Medication, News
Tags: cancer, pioglitazone, rosiglitazone

Categories: Medication
Tags: cancer, pioglitazone, rosiglitazone

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Napp DiabetesSanofi DiabetesNovo NordiskAstraZeneca

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)AmgenAbout Ascensia Diabetes CareAbbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 Empagliflozin exenatide GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes USA Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership